ᐈ Cytomos Revolutionizes Advanced Therapy Manufacturing with Cell Characterization Tech

📢 Cytomos, a company with expertise in semiconductors, is developing a technology to efficiently characterize cells for advanced therapy manufacturing. 🧪 They use electrical fields to measure cell properties and create a unique digital fingerprint of each cell. 📊 This technology can monitor cell manufacturing processes and detect deviations that could lead to batch failures. 💡 Cytomos aims to offer products and services by Q2 2024.

📢 Cytomos Revolutionizes Cell Manufacturing with Cutting-Edge Technology

Introduction:

Cytomos is a company that specializes in using electrical fields to measure cell properties for advanced therapy medicinal products (ATMPs). By creating a unique digital fingerprint of cells, Cytomos can monitor cell manufacturing processes and detect any deviations that may lead to batch failure. This technology offers a different approach compared to traditional methods such as flow cytometry and metabolite monitoring.

Main points:

Cytomos uses electrical fields to measure cell properties for ATMPs.
The technology creates a digital fingerprint of cells to monitor manufacturing processes.
Deviation from the cell profile can indicate issues during development.
The shape of induced pluripotent stem cells can be used to monitor their transformation.
Cytomos plans to offer products and services to early adopters in 2024.

Conclusion:

Cytomos’ innovative use of electrical fields to measure cell properties has the potential to greatly improve the monitoring and manufacturing of advanced therapy medicinal products. By detecting deviations and ensuring the correct transformation of cells, this technology could streamline ATMP development processes and improve overall quality control. Cytomos’ planned launch of products and services in 2024 is an exciting development for the field of biomanufacturing.